The following is a summary of “Allergic fungal rhinosinusitis linked to other hyper-IgE syndromes through defective TH17 ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Have you ever been frustrated by one side of your nose feeling completely blocked while the other is clear? As annoying as it ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and congestion in CRSwNP.

Many things can cause sinus pressure and pain, such as sinus infections, nasal allergies, nasal polyps, septal deviations as well as enlarged vascular structures in the nose called turbinates. “Sinus ...

TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...